Osteoarthritis is the most prevalent arthritis worldwide and is characterised by chronic pain and impaired physical function. Millions of people across the UK suffer from debilitating hand pain due to the condition and the usual care is ibuprofen and anti-inflammatory drugs.
Patients are usually also sent for hand physiotherapy, but some say they can’t continue the therapy because of the pain. However, taking part in hand physiotherapy is proven to be beneficial in the long term in preventing hands from losing movement.
The study by staff at St George’s University of London, showed that a drug called pregabalin was the most effective trial treatment. Patients took two pills daily and were treated during a three month period.
Dr Nidhi Sofat, a Reader in Rheumatology, said: “Osteoarthritis is the most common form of arthritis in the world and more than 8m people have it in the UK.
“Usually, drug trials for arthritis are aimed at helping patients with problems in their knees or hips, but we wanted to focus on hands as no one had really investigated that area before.
“To tackle the pain would mean an improvement in the general wellbeing and care of patients with this condition. This led us to run a trial to try to switch off the pain receptors in the brain to enable patients to manage their condition more easily.
“They reported an improvement in not only pain, but also their abilities to do daily tasks like cooking, washing dressing. They also used six times less extra pain relief than the placebo group.”
The trial involved giving 65 patients different medication and monitoring their progress. During the drugs trial patients were split into groups and one group took pregabalin, the second group took duloxetine and the third group took placebo pills.
All the drugs looked the same so the patients did not know what they were taking.
Certain people are more prone to osteoarthritis in the hands, for example, women aged over 50.
The study was funded by Rosetrees’ Trust and the National Institute for Health Research (NIHR).
The proof-of-concept trail has been published in The Journal of Pain Research.
Source: Alpha Galileo